
Purchase 1B-LSD
Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 1B-LSD for sale
1B-LSD (also known as N1-butyryl or BOL-148) is an acylated derivative of lysergic acid diethylamide (LSD). 1B-LSD has been sold as a designer drug and psychoactive research chemical, first appearing on the online research chemical market in 2017.
1B-LSD, also known as BOL-148 or N1-butyryl, is an acylated derivative of lysergic acid diethylamide or LSD that was first synthesized in 2017. The compound has been sold online since early 2017 as a designer drug and psychoactive "recreational chemical."
1B-LSD (1-butyryl-lysergic acid diethylamide) is a psychedelic substance of the lysergamide class. It is a homolog of LSD, in which the diethylamide functional group has been replaced with a butyryl group. It is thought to be roughly one-seventh as potent as LSD, with an efficacy of around 30% at LSD's active dose.
1B-LSD is an acylated derivative of lysergic acid diethylamide (LSD). 1B-LSD has been used to study the serotonin system.
1B-LSD is a controlled substance in New Zealand.
1B-LSD is an analog of lysergic acid diethylamide (LSD), a psychedelic drug known for its ability to alter one's state of consciousness. Test performed on mice showed that 1B-LSD was active at around 1/7 the potency of LSD itself, putting it roughly in the same range as 2C-E.
1B-LSD is a psychedelic drug analog of lysergic acid diethylamide (LSD). 1B-LSD is a lysergamide, specifically a derivative of lysergic acid. Its systematic name is N-benzoyl-N-(1-butanol)-lysergic acid diethylamide. Alexander Shulgin first synthesized the drug and reported in his book TiHKAL (Tryptamines I Have Known And Loved) under the code name "BOL-148".
1B-LSD is a psychedelic drug analog of lysergic acid diethylamide (LSD). It is a lysergamide, specifically a derivative of lysergic acid. Its systematic name is N-benzoyl-N-(1-butanol)-lysergic acid diethylamide.
1B-LSD is a psychedelic drug analog of lysergic acid diethylamide (LSD).
There have been no formal clinical studies by mainstream scientists and researchers of N1-Butyl-Lysergic Acid Diethylamide (also known as 1B-LSD or 1B-LAD) before its classification as a Schedule I Drug. We have created a web page and published information about this new psychoactive substance.
It is illegal to possess 1B-LSD, so we created this page because there is so little information available online. We want to share the facts about this new, unregulated substance with users and non-users alike.
The novel lysergamide derivative 1B-LSD is a new psychedelic substance of the lysergamide family. It is being sold as a designer drug under various names and marketed as an alternative to LSD and LSA.
LSD (Lysergic acid diethylamide) is a psychedelic drug known for its ability to alter the senses and cause hallucinations. It causes unconsciousness in high doses.
1B-LSD (1B-lysergic acid diethylamide) is an acylated derivative of LSD. It appears as a white, odorless powder. 1B-LSD is not scheduled at the federal level in the United States but may be considered an analog (of LSD) and is therefore illegal to sell for human consumption or possess in the United States under Schedule I(c) of the Controlled Substances Act.
Our 1B-LSD is a non-psychoactive substance, classified as a tryptamine. It is considered an N-acyl derivative of lysergic acid diethylamide (LSD). We provide this product for research purposes only and strongly advise against human consumption.
1B-LSD is an analog of lysergic acid diethylamide. It is closely related to LSD and has similar effects but with a slightly more psychedelic headspace. This compound has been linked to local deaths resulting from an overdose.
The N-butyryl group makes the compound an analog of LSD and, therefore -like it- a class A drug.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
200g $590
100mg $840
200g $690
500g $1080
500g $1300
100g $510
out of stock
300g $970
1kg $1590
1kg $1690
out of stock